Faktor-Xa-Inhibitoren
Antikoagulantien der Antistasin-Familie, die auf den Konvergenzpunkt der Gerinnungskaskade abzielen
Zuletzt aktualisiert: June 18, 2026
Mechanismus-Haftungsausschluss
Factor Xa occupies a uniquely strategic position in the Gerinnungskaskade — it sits at the convergence of the intrinsic and extrinsic pathways, and a single molecule of Factor Xa generates approximately 1,000 molecules of thrombin through the prothrombinase complex. Leech-derived Factor Xa inhibitors (FXaI) belong to the antistasin superfamily and provided conceptual validation that ultimately led to the oral Factor Xa inhibitor drug class.
Molekulare Eigenschaften
| Form | MG | Ki (Amidolytic) | Ki (Prothrombinase) | Anmerkung |
|---|---|---|---|---|
| Native FXaI | 13–14 kDa (85 AS) | ~1 pM | 72–120 nM | Isolated from SGS; limited supply |
| Rekombinant FXaI (r-FXaI) | 14,4 kDa (133 AS) | ~10 nM | ~0.04 nM | Superior prothrombinase inhibition |
FXaI belongs to the antistasin superfamily with approximately 50% sequence homology to antistasin from Haementeria officinalis. The native form (85 Aminosäuren, 13–14 kDa) is smaller than the recombinant construct (133 Aminosäuren, 14.4 kDa), which includes zusätzlich sequence for improved expression and stability.
Präklinische Überlegenheit
r-FXaI vs. Heparin
Zeelon et al. (1997) demonstrated that recombinant FXaI was superior to heparin in animal thrombosis models. r-FXaI achieved greater antithrombotic efficacy with less bleeding risk — a therapeutic index advantage attributable to selective Factor Xa inhibition versus heparin’s broad antithrombin-mediated mechanism. Notably, r-FXaI showed dramatically improved prothrombinase complex inhibition (Ki ~0.04 nM) verglichen mit the native form, suggesting the recombinant construct better mimics the physiological inhibitory conformation.
Pharmazeutisches Erbe — orale Faktor-Xa-Inhibitoren
The conceptual pathway from leech FXaI to the modern Factor Xa inhibitor drug class represents eine der clearest bench-to-bedside translations in zoopharmacology. Leech antistasin Forschung validated Factor Xa as a druggable target, leading to the development of oral small-molecule inhibitors that now represent der dominante oral Antikoagulans market.
| Wirkstoff | FDA | Indikation | Mechanismus |
|---|---|---|---|
| Rivaroxaban (Xarelto) | 2011 | TVT/LE, Schlaganfallprävention bei VHF, post-chirurgische Prophylaxe | Direkter, reversibler FXa-Inhibitor am aktiven Zentrum |
| Apixaban (Eliquis) | 2012 | Schlaganfallprävention bei VHF, Behandlung und Prophylaxe von TVT/LE | Direkter, reversibler FXa-Inhibitor am aktiven Zentrum |
| Edoxaban (Savaysa) | 2015 | Schlaganfallprävention bei VHF, Behandlung TVT/LE | Direkter, reversibler FXa-Inhibitor am aktiven Zentrum |
LCI — Carboxypeptidase B Inhibitor
Maintaining Fibrinolytic Susceptibility
LCI (Leech Carboxypeptidase Inhibitor) is a companion Antikoagulans molecule that targets thrombin-activatable fibrinolysis inhibitor (TAFI). TAFI normally removes C-terminal lysine residues from partially degraded fibrin, reducing plasminogen binding and slowing clot lysis. By inhibiting TAFI-mediated carboxypeptidase B activity, LCI maintains fibrinolytic susceptibility of the clot — synergizing with destabilase’s direct fibrinolytic action and hirudin’s prevention of TAFI activation.
Antistasin-Superfamilie
The antistasin superfamily — named after antistasin from Haementeria officinalis — includes mehrere blutegelbasiert inhibitors sharing a conserved cysteine-rich scaffold with characteristic disulfide bonding patterns. Members include FXaI, bdellastatin (bdellin A), and hirustasin. The superfamily represents eine der most pharmaceutically productive structural families in zoopharmacology, having contributed to the conceptual validation of sowohl the Factor Xa inhibitor and direkter Thrombin-Inhibitor drug classes.
Verwandte Ressourcen
Decorsin & Ornatin
RGD-haltige antithrombozytäre Peptide aus Blutegeln der Neuen Welt.
Hirudin-ähnliche Faktoren
Thrombin-Inhibitoren mit femtomolarer Affinität.
Direkte Thrombin-Inhibitoren
Die DTI-Wirkstoffklasse von Hirudin bis Dabigatran.
Verbindungsreferenz
Vollständige Datenbank bioaktiver SDS-Komponenten.
Compound Coverage Map
Factor Xa inhibitors and the broader leech anticoagulant arsenal (107 compounds catalogued).
Research Roadmap
Open questions on antistasin, LFTI, and the engineered-variant pipeline.